25 related articles for article (PubMed ID: 9384662)
21. Lymphocyte-conditioned medium in combination with interleukin-2 effectively induces antitumour autoimmunity by adoptive transfer of short activated killer (SHAK) cells.
Buer J; Hilse R; Dallmann I; Grosse J; Kirchner H; Zorn U; Hänninen EL; Franzke A; Duensing S; Poliwoda H
Cytokines Mol Ther; 1995 Mar; 1(1):39-46. PubMed ID: 9384662
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
[TBL] [Abstract][Full Text] [Related]
23. Lymphocyte therapy of renal cell carcinoma.
Dillman RO
Expert Rev Anticancer Ther; 2005 Dec; 5(6):1041-51. PubMed ID: 16336095
[TBL] [Abstract][Full Text] [Related]
24. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
Thompson JA; Benyunes MC; Bianco JA; Fefer A
Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
[No Abstract] [Full Text] [Related]
25. Adoptive cellular therapy.
Hoffman DM; Gitlitz BJ; Belldegrun A; Figlin RA
Semin Oncol; 2000 Apr; 27(2):221-33. PubMed ID: 10768601
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
